Gatralimab (GZ-402668) is a next-generation humanized anti-CD52 monoclonal antibody for which phase 1 clinical trial data indicate it successfully achieves the intended pharmacodynamic effect of lymphocyte depletion followed by subsequent repopulation, all with an acceptable safety profile, supporting its further investigation about relapsing-remitting multiple sclerosis (MS).
Reinheit:
95%
CAS Nummer:
[1826020-80-7]
Target-Kategorie:
NF-kappaB
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
